After removing germline mutations, the total somatic mutations in the tumor genome are known as tumor mutation burden (TMB), which can activate CD8+cytotoxic T cells and initiate T cell-mediated anti-tumor effects (56). This evidence concerns the gene CD8A and neoplasm.